Abstract :Objective To study the effect of Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) combined with recombinant human epidermal growth factor in the treatment of refractory diabetic skin ulcers. Methods A total of 70 patients with refractory diabetic skin ulcers admitted to the Center for Disease Control and Prevention of Nanping City, Fujian Province from January 2021 to March 2022 were enrolled and divided into two groups using the random number table method. The control group was treated with Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) (a total of 35 cases), and the study group was treated with Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) combined with recombinant human epidermal growth factor (a total of 35 cases). The therapeutic effects of the two groups were compared. Results After treatment, the fasting blood glucose, 2-hour postprandial blood glucose levels and ulcer area in the study group were lower than those in the control group; compared with the control group, the total effective rate of the study group was higher, and the myogenic time, septic removal time, healing time and number of dressing changes were lower, and the differences were statistically significant ( P<0.05). Conclusion The use of Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) combined with recombinant human epidermal growth factor in the treatment of patients with refractory diabetic skin ulcers can reduce the blood glucose level of patients and promote ulcer healing.
Liu Guoxing. Analysis of the efficacy of compound polymyxin B ointment combined with recombinant human epidermal growth factor in the treatment of diabetic skin refractory ulcers[J]. New World of Diabetes, 2023, 26(07): 72-75.